Study shows BSGI effective in breast imaging
Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC) – a type of breast cancer that begins in the milk-producing glands (lobules) and then spreads to the surrounding breast tissue – according to a study published in the February 2009 issue of American Journal of Roentgenology. The study found BSGI provides better sensitivity for detecting ILC than mammography, ultrasound and magnetic resonance imaging. BSGI, performed with the Dilon (Newport News, Virginia) 6800 Gamma Camera, is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers.
"The study is significant because ILC can often be difficult to detect mammographically and is often not palpable at clinical examination. BSGI offers improved detection of this form of breast cancer that affects approximately 10% of new breast cancer patients every year," said Rachel Brem, director of breast imaging and intervention at George Washington University Medical Center (Washington).
Innocoll says CollaRx testing is now underway
Innocoll (Ashburn, Virginia) said that the last patient has been dosed in the first of two ongoing U.S. Phase III clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies, to investigate CollaRx Gentamicin Surgical Implant for the prevention of surgical site infections.
The CollaRx is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold.
Nasdaq extends suspension for VirtualScopics
VirtualScopics (Rochester, New York) reported that the Nasdaq Stock Market has further extended the temporary suspension of the $1 minimum bid price requirement until July 20. The company now has until Nov. 9 to regain compliance with the requirement. VirtualScopics said it has received stockholder approval to effectuate a reverse stock split, through May 9, in the event that the minimum bid price has not been achieved.
The company said it intends to request an extension from its stockholders to take advantage of the additional time allowed by Nasdaq to regain compliance. VirtualScopics provides imaging solutions designed to accelerate drug and medical device development.